You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,374,782


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,374,782
Title:Production of microspheres
Abstract: Protein microspheres are produced by contacting an aqueous solution of a macromolecule and a polymer with a surface at a high surface area to volume ratio, and heating the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions which can be delivered to a patient by inhalation therapy.
Inventor(s): Brown; Larry R. (Newton, MA)
Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (CH)
Application Number:10/399,829
Patent Claims:1. A process for preparing microspheres comprising the steps of combining a macromolecule and a polymer in an aqueous solution, wherein the polymer is water soluble or soluble in a water miscible solvent, contacting a volume of the aqueous solution with a surface at a surface area to volume ratio of at least about 6.5 cm.sup.-1, heating the aqueous solution, and forming the microspheres continuously in the aqueous solution in a continuous process.

2. The process of claim 1 wherein the surface area to volume ratio is at least about 14 cm.sup.-1.

3. The process of claim 1 wherein the surface is a hydrophobic surface.

4. The process of claim 3 wherein the hydrophobic surface is formed from a material selected from metals, ceramics and glass.

5. The process of claim 4 wherein the metal is stainless steel.

6. The process of claim 3 wherein the hydrophobic surface is formed from a hydrophobic polymer.

7. The process of claim 6 wherein the hydrophobic polymer is selected from the group consisting of polypropylene, polystyrene, Teflon and silicone polymers.

8. The process of claim 1 wherein the macromolecule is selected from the group consisting of proteins, peptides, nucleic acids, carbohydrates, protein conjugates viruses, virus particles, and mixtures thereof.

9. The process of claim 8 wherein the macromolecule is a peptide.

10. The process of claim 9 wherein the peptide is a polypeptide.

11. The process of claim 8 wherein the macromolecule is a carbohydrate.

12. The process of claim 11 wherein the carbohydrate is a polysaccharide.

13. The process of claim 8 wherein the macromolecule is a protein.

14. The process of claim 13 wherein the protein is a therapeutic protein.

15. The process of claim 14 wherein the protein is selected from the group consisting of insulin, human serum albumin, human growth hormone, parathyroid hormone and calcitonin.

16. The process of claim 1 wherein the microspheres have a mean diameter in the range of from about 0.1 microns to about 10.0 microns.

17. The process of claim 16 wherein the microspheres have a mean diameter in the range of from about 0.5 microns to about 5.0 microns.

18. The process of claim 17 wherein the microspheres have a mean diameter in the range of from about 1.0 microns to about 2.0 microns.

19. The process of claim 1 wherein the aqueous solution of macromolecule and polymer is heated to a temperature in the range of from about 37.degree. C. to about 95.degree. C. for a time period of about 1 minute to about 24 hours.

20. The process of claim 1 wherein the polymer is selected from the group consisting of carbohydrate polymers, polyaliphatic alcohols, poly(vinyl) polymers, polyacrylic acids, polyorganic acids, polyamino acids, polyethers, naturally occurring polymers, polyimides, polyesters, polyaldehydes, co-polymers, block co-polymers, terpolymers, surfactants, branched polymers, cyclo-polymers, and mixtures thereof.

21. The process of claim 20 wherein the polymer is selected from the group consisting of dextran, polyethylene glycol, polyvinyl pyrrolidone, co-polymers of polyethylene glycol and polyvinyl pyrrolidone, polyvinyl alcohol, co-polymers of polyoxyethylene and polyoxypropylene, and mixtures thereof.

22. The process of claim 21 wherein the polymer is a co-polymer of polyethylene glycol and polyvinyl pyrrolidone, or a co-polymer of polyoxyethylene and polyoxypropylene.

23. The process of claim 1 wherein the microspheres comprise greater than about 90% macromolecule by weight.

24. The process of claim 23 wherein the microspheres comprise greater than about 95% macromolecule by weight.

25. The process of claim 24 wherein the microspheres comprise greater than about 99% macromolecule by weight.

26. A product prepared according to the continuous process of claim 1.

27. The process of claim 1 wherein the contacting of the aqueous solution with the surface comprises moving the aqueous solution continuously over the surface.

28. The process of claim 27 wherein the aqueous solution is moved with a pump.

29. The process of claim 27 wherein the aqueous solution is moved at a speed of about 0.4 ml/minute.

30. The process of claim 1 wherein the surface is the inner surface of a tubing.

31. The process of claim 30 wherein the tubing has an inner diameter of 1/32 inches to 1/8 inches.

32. The process of claim 1 further comprising combining additional polymers with the macromolecule and the polymer in the aqueous solution.

33. The process of claim 1 wherein the heating comprises exposing the solution to heat, radiation or ionization.

34. The process of claim 33 wherein the radiation is microwave radiation.

35. The process of claim 33 wherein the heat, radiation or ionization is used in combination with sonication, vortexing, mixing or stifling.

36. The process of claim 1, further comprising allowing the microspheres to continuously flow through for collection.

Details for Patent 7,374,782

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 10/28/1982 ⤷  Try a Trial 2020-10-27
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 12/29/2015 ⤷  Try a Trial 2020-10-27
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 08/06/1998 ⤷  Try a Trial 2020-10-27
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 03/31/1994 ⤷  Try a Trial 2020-10-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.